Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.

Oliver Dorigo,Janos L. Tanyi,James Strauss,Amit M. Oza,Tanja Pejovic,Prafull Ghatage,J.A. Villella,Stephan Fiset,Lisa MacDonald,Lance Leopold, Gabriela Nicola Rosu

Journal of Clinical Oncology（2018）

引用 9|浏览24

暂无评分

摘要

5510Background: DPX-Survivac is a novel T cell activating therapy containing a mix of HLA class I peptides designed to evoke a T cell response against survivin and previously optimized for immunoge...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要